A functional screening of the kinome identifies the Polo‐like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain
Pediatric Blood & Cancer2017Vol. 64(11)
Citations Over TimeTop 16% of 2017 papers
Simone Treiger Sredni, Mario Suzuki, Jianping Yang, Jacek Topczewski, Anders W. Bailey, Tufan Gökirmak, Jeffrey N. Gross, Alexandre Lima de Andrade, Akihide Kondo, David R. Piper, Tadanori Tomita
Abstract
Our findings indicate that rhabdoid tumor cell proliferation is highly dependent on PLK4 and suggest that targeting PLK4 with small-molecule inhibitors may hold a novel strategy for the treatment of MRT and possibly other embryonal tumors of the brain. This is the first time that PLK4 has been described as a potential target for both brain and pediatric tumors.
Related Papers
- → Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases(2019)21 cited
- → PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor(2020)18 cited
- → Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships(2020)7 cited
- → Structure Activity Relationship Studies around DB18, a Potent and Selective Inhibitor of CLK Kinases(2022)3 cited
- SHEDding light on the role of Pragmin pseudo-kinases in cancer.(2019)